Alpelisib patent application 2009 novartis ag?

What is Alpelisib, and who applied for its patent?

Alpelisib, also known as BYL719, is a small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) delta and gamma isoforms, which plays a crucial role in cell signaling pathways [1]. This drug targets PI3K, a protein that helps cancer cells grow and survive in tumors.

In November 2009, Novartis AG filed a patent application for Alpelisib with the United States Patent and Trademark Office (USPTO) [2].

How has the patent situation for Alpelisib evolved?

As per DrugPatentWatch.com, Alpelisib's US patent was granted in 2014, and it was initially set to expire in 2027 [3]. However, the patent's expiration date has been shifted due to various extensions granted by the patent office.

What are the implications of the patent situation for Alpelisib?

The patent situation for Alpelisib has significant implications for the pharmaceutical industry, as it affects the exclusivity and pricing of the drug. The extended patent protection has allowed Novartis to maintain its market share and control over the production and distribution of Alpelisib.

However, once the patent expires, other pharmaceutical companies may develop and market biosimilars or generic versions of Alpelisib, which could lead to reduced prices and increased competition in the market [4].

Sources:

[1] https://en.wikipedia.org/wiki/Alpelisib
[2] United States Patent Application 12/625251, filed November 18, 2009
[3] DrugPatentWatch.com: Alpelisib (BYL719)
[4] DrugPatentWatch.com: Biosimilars and Generic Drugs

Note: The sources cited above are for information purposes only and may not reflect the most up-to-date information on the patent situation for Alpelisib. It's essential to consult the official patent filings and regulatory websites for the most accurate and current information.